Soligenix Inc. (SNGX) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
29 EMMONS DRIVE PRINCETON, NJ 08540 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Receivables | 195 | 89 | 139 | 243 | 219 | 231 | |||
| Prepaid expense | 866 | 584 | 171 | 213 | 274 | 396 | |||
| Deferred costs | |||||||||
| Other undisclosed current assets | 8,446 | 10,299 | 13,161 | 10,266 | 13,360 | 16,866 | |||
| Total current assets: | 9,507 | 10,972 | 13,471 | 10,722 | 13,853 | 17,493 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 230 | 258 | 287 | 314 | 341 | 367 | |||
| Property, plant and equipment | 12 | 14 | 15 | 17 | 18 | 22 | |||
| Capitalized contract cost, net | 25 | 18 | 13 | 6 | 24 | 22 | |||
| Deposits noncurrent assets | 23 | 23 | 23 | 23 | 23 | 23 | |||
| Deferred costs | 18 | 18 | 20 | 20 | 20 | ||||
| Total noncurrent assets: | 290 | 331 | 355 | 380 | 427 | 454 | |||
| TOTAL ASSETS: | 9,797 | 11,303 | 13,826 | 11,102 | 14,280 | 17,947 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 3,529 | 3,848 | 4,819 | 5,220 | 6,174 | 6,460 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 60 | ||
| Accounts payable | 1,111 | 1,461 | 2,472 | 2,769 | 3,866 | 4,165 | |||
| Accrued liabilities | 2,418 | 2,387 | 2,346 | 2,451 | 2,308 | 2,235 | |||
| Deferred revenue | 100 | ||||||||
| Debt | 2,250 | 1,500 | 750 | 6,000 | 9,898 | 3,000 | |||
| Other undisclosed current liabilities | 373 | 174 | 189 | 157 | 446 | 106 | |||
| Total current liabilities: | 6,152 | 5,522 | 5,758 | 11,377 | 16,517 | 9,666 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 262 | ||||||||
| Liabilities, other than long-term debt | 112 | 144 | 174 | 204 | 234 | 100 | |||
| Deferred revenue | 100 | ||||||||
| Operating lease, liability | 112 | 144 | 174 | 204 | 234 | 262 | |||
| Other undisclosed noncurrent liabilities | 1,011 | 1,416 | 2,094 | 2,908 | 6,887 | ||||
| Total noncurrent liabilities: | 1,123 | 1,560 | 2,268 | 3,112 | 234 | 7,249 | |||
| Total liabilities: | 7,275 | 7,082 | 8,026 | 14,489 | 16,751 | 16,915 | |||
| Temporary equity, carrying amount | 0 | ||||||||
| Equity | |||||||||
| Equity, attributable to parent | 2,522 | 4,221 | 5,800 | (3,387) | (2,471) | 1,032 | |||
| Common stock | 10 | 10 | 10 | 3 | 3 | 43 | |||
| Additional paid in capital | 228,194 | 228,071 | 228,006 | 217,207 | 217,065 | 216,773 | |||
| Accumulated other comprehensive income | 22 | 24 | 6 | 13 | 25 | 25 | |||
| Accumulated deficit | (225,704) | (223,884) | (222,222) | (220,610) | (219,563) | (215,810) | |||
| Total equity: | 2,522 | 4,221 | 5,800 | (3,387) | (2,471) | 1,032 | |||
| TOTAL LIABILITIES AND EQUITY: | 9,797 | 11,303 | 13,826 | 11,102 | 14,280 | 17,947 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 245 | 130 | 207 | 257 | 366 | 166 | ||
| Cost of revenue | (222) | (110) | (184) | (226) | (136) | (129) | ||
| Gross profit: | 23 | 20 | 23 | 31 | 230 | 37 | ||
| Operating expenses | (2,161) | (1,799) | (1,653) | (2,182) | (3,800) | (3,118) | ||
| Operating loss: | (2,138) | (1,779) | (1,630) | (2,151) | (3,570) | (3,081) | ||
| Nonoperating income (expense) | (289) | 116 | 18 | (57) | (184) | (228) | ||
| Gain (loss), foreign currency transaction, before tax | 1 | (3) | 4 | (0) | (13) | |||
| Other nonoperating income | 2 | 41 | ||||||
| Interest and debt expense | (394) | |||||||
| Loss from continuing operations before equity method investments, income taxes: | (2,427) | (1,663) | (2,006) | (2,207) | (3,754) | (3,309) | ||
| Other undisclosed income from continuing operations before income taxes | 394 | |||||||
| Loss from continuing operations before income taxes: | (2,427) | (1,663) | (1,612) | (2,207) | (3,754) | (3,309) | ||
| Income tax benefit | 607 | 1,161 | 1,155 | |||||
| Loss from continuing operations: | (1,820) | (1,663) | (1,612) | (1,046) | (3,754) | (2,154) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | (2,154) | |
| Net loss: | (1,820) | (1,663) | (1,612) | (1,046) | (3,754) | (2,154) | ||
| Other undisclosed net loss attributable to parent | (1,155) | |||||||
| Net loss available to common stockholders, diluted: | (1,820) | (1,663) | (1,612) | (1,046) | (3,754) | (3,309) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (1,820) | (1,663) | (1,612) | (1,046) | (3,754) | (2,154) | ||
| Comprehensive loss: | (1,820) | (1,663) | (1,612) | (1,046) | (3,754) | (2,154) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (2) | 18 | (7) | (12) | (1) | (1,141) | ||
| Comprehensive loss, net of tax, attributable to parent: | (1,822) | (1,644) | (1,619) | (1,058) | (3,754) | (3,295) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.